Synthesis of novel anilinoquinolines as c-fms inhibitors.
A novel series of potent substituted anilinoquinolines were discovered as c-fms inhibitors. The potency could be manipulated upon modification of the C4 aniline and C7 aryl functionality. Pharmacokinetic analysis identified a metabolically stable analog suitable for further investigative work.
Smalley
Terrence L
TL
GlaxoSmithKline, Inc., Five Moore Drive, Research Triangle Park, NC 27709, USA. terry.l.smalley@gsk.com
Chamberlain
Stanley D
SD
Mills
Wendy Y
WY
Musso
David L
DL
Randhawa
Sab A
SA
Ray
John A
JA
Samano
Vicente
V
Frick
Lloyd
L
D000814:Aniline Compounds / Q000737:chemistry*; D000818:Animals; D001665:Binding Sites; D002460:Cell Line; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D020128:Inhibitory Concentration 50; D023421:Models, Animal; D008958:Models, Molecular; D015394:Molecular Structure; D011804:Quinolines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D016186:Receptor, Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D000814:Aniline Compounds; D011804:Quinolines; D016186:Receptor, Macrophage Colony-Stimulating Factor; C023650:aniline